IN2014MN02082A - - Google Patents
Info
- Publication number
- IN2014MN02082A IN2014MN02082A IN2082MUN2014A IN2014MN02082A IN 2014MN02082 A IN2014MN02082 A IN 2014MN02082A IN 2082MUN2014 A IN2082MUN2014 A IN 2082MUN2014A IN 2014MN02082 A IN2014MN02082 A IN 2014MN02082A
- Authority
- IN
- India
- Prior art keywords
- formula
- disclosed
- methods
- administering
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
- A61K31/31—Mercury compounds containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614274P | 2012-03-22 | 2012-03-22 | |
| PCT/US2013/032575 WO2013142382A1 (en) | 2012-03-22 | 2013-03-15 | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02082A true IN2014MN02082A (pl) | 2015-08-21 |
Family
ID=49223277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2082MUN2014 IN2014MN02082A (pl) | 2012-03-22 | 2013-03-15 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8877763B2 (pl) |
| EP (1) | EP2828259B1 (pl) |
| JP (1) | JP6101341B2 (pl) |
| KR (1) | KR102011770B1 (pl) |
| CN (1) | CN104428298B (pl) |
| AU (1) | AU2013235344B2 (pl) |
| BR (1) | BR112014023460B1 (pl) |
| CA (1) | CA2868156C (pl) |
| CL (1) | CL2014002505A1 (pl) |
| EA (1) | EA031267B1 (pl) |
| ES (1) | ES2694223T3 (pl) |
| HK (1) | HK1208453A1 (pl) |
| IL (1) | IL234802B (pl) |
| IN (1) | IN2014MN02082A (pl) |
| MX (1) | MX360912B (pl) |
| MY (1) | MY184858A (pl) |
| NZ (1) | NZ700283A (pl) |
| PL (1) | PL2828259T3 (pl) |
| SG (1) | SG11201405942RA (pl) |
| TR (1) | TR201816480T4 (pl) |
| WO (1) | WO2013142382A1 (pl) |
| ZA (1) | ZA201407588B (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102228034B1 (ko) * | 2013-10-21 | 2021-03-16 | 제노스코 | 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도 |
| CN105272930B (zh) * | 2014-07-17 | 2018-07-13 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
| KR20160035411A (ko) * | 2014-09-23 | 2016-03-31 | 주식회사 오스코텍 | LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물 |
| KR20170087913A (ko) | 2014-11-17 | 2017-07-31 | 로드아일랜드하스피틀 | 나노물질, 조성물, 합성, 및 어셈블리 |
| JP7200453B2 (ja) * | 2018-06-27 | 2023-01-10 | オスコテック インコーポレイテッド | Ａｘｌ阻害剤として使用するためのピリドピリミジノン誘導体 |
| KR20200022712A (ko) * | 2018-08-23 | 2020-03-04 | 주식회사 오스코텍 | 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법 |
| KR102230721B1 (ko) | 2019-02-01 | 2021-03-22 | 주식회사 오스코텍 | 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법 |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| CN110327347B (zh) * | 2019-08-16 | 2021-06-01 | 陕西科技大学 | G-749在制备抗真菌药物中的应用 |
| TWI759829B (zh) * | 2019-08-23 | 2022-04-01 | 財團法人生物技術開發中心 | 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物 |
| CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
| WO2023225005A1 (en) | 2022-05-17 | 2023-11-23 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
| KR102440707B1 (ko) | 2022-07-10 | 2022-09-05 | 이우미 | 공장 추천 시스템 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20022521A3 (cs) * | 2000-01-27 | 2003-02-12 | Warner-Lambert Company | Pyridopyrimidinonové deriváty pro léčení neurodegenerativních onemocnění |
| DE60111752T2 (de) * | 2000-08-31 | 2006-05-04 | F. Hoffmann-La Roche Ag | 7-oxopyridoryrimidine |
| KR100571339B1 (ko) * | 2000-08-31 | 2006-04-17 | 에프. 호프만-라 로슈 아게 | 세포증식 억제제로서의 7-옥소 피리도피리미딘 |
| EP2025678A1 (en) * | 2007-08-17 | 2009-02-18 | Oncalis AG | Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase |
| TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| ES2432414T3 (es) * | 2008-08-12 | 2013-12-03 | Glaxosmithkline Llc | Compuestos químicos |
| US8338481B2 (en) * | 2009-01-28 | 2012-12-25 | Ramot At Tel-Aviv University Ltd. | Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer |
| JP2013502429A (ja) * | 2009-08-19 | 2013-01-24 | アムビト ビオスシエンセス コルポラチオン | ビアリール化合物及びその使用方法 |
| CN102695416B (zh) * | 2009-10-29 | 2017-03-08 | 金纳斯克公司 | 激酶抑制剂 |
-
2013
- 2013-03-15 CN CN201380025782.8A patent/CN104428298B/zh active Active
- 2013-03-15 BR BR112014023460-4A patent/BR112014023460B1/pt active IP Right Grant
- 2013-03-15 PL PL13763998T patent/PL2828259T3/pl unknown
- 2013-03-15 ES ES13763998.5T patent/ES2694223T3/es active Active
- 2013-03-15 EP EP13763998.5A patent/EP2828259B1/en active Active
- 2013-03-15 CA CA2868156A patent/CA2868156C/en active Active
- 2013-03-15 US US13/841,827 patent/US8877763B2/en active Active
- 2013-03-15 JP JP2015501823A patent/JP6101341B2/ja active Active
- 2013-03-15 NZ NZ700283A patent/NZ700283A/en unknown
- 2013-03-15 MX MX2014011354A patent/MX360912B/es active IP Right Grant
- 2013-03-15 SG SG11201405942RA patent/SG11201405942RA/en unknown
- 2013-03-15 KR KR1020147029509A patent/KR102011770B1/ko active IP Right Grant
- 2013-03-15 IN IN2082MUN2014 patent/IN2014MN02082A/en unknown
- 2013-03-15 EA EA201491747A patent/EA031267B1/ru not_active IP Right Cessation
- 2013-03-15 WO PCT/US2013/032575 patent/WO2013142382A1/en active Application Filing
- 2013-03-15 TR TR2018/16480T patent/TR201816480T4/tr unknown
- 2013-03-15 MY MYPI2014702705A patent/MY184858A/en unknown
- 2013-03-15 AU AU2013235344A patent/AU2013235344B2/en active Active
-
2014
- 2014-09-22 IL IL234802A patent/IL234802B/en active IP Right Grant
- 2014-09-22 CL CL2014002505A patent/CL2014002505A1/es unknown
- 2014-10-20 ZA ZA2014/07588A patent/ZA201407588B/en unknown
-
2015
- 2015-09-16 HK HK15109075.2A patent/HK1208453A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL234802B (en) | 2018-10-31 |
| CN104428298A (zh) | 2015-03-18 |
| NZ700283A (en) | 2016-08-26 |
| MY184858A (en) | 2021-04-27 |
| KR20140144709A (ko) | 2014-12-19 |
| EP2828259A4 (en) | 2015-08-19 |
| CN104428298B (zh) | 2017-03-01 |
| AU2013235344A1 (en) | 2014-10-09 |
| JP2015510942A (ja) | 2015-04-13 |
| JP6101341B2 (ja) | 2017-03-22 |
| US8877763B2 (en) | 2014-11-04 |
| CA2868156C (en) | 2020-07-28 |
| US20130274274A1 (en) | 2013-10-17 |
| KR102011770B1 (ko) | 2019-08-19 |
| EA201491747A1 (ru) | 2015-10-30 |
| ES2694223T3 (es) | 2018-12-19 |
| CL2014002505A1 (es) | 2015-10-02 |
| MX360912B (es) | 2018-11-22 |
| EP2828259B1 (en) | 2018-08-08 |
| BR112014023460B1 (pt) | 2020-09-01 |
| CA2868156A1 (en) | 2013-09-26 |
| PL2828259T3 (pl) | 2019-02-28 |
| ZA201407588B (en) | 2015-11-25 |
| TR201816480T4 (tr) | 2018-11-21 |
| WO2013142382A1 (en) | 2013-09-26 |
| MX2014011354A (es) | 2014-12-05 |
| EP2828259A1 (en) | 2015-01-28 |
| SG11201405942RA (en) | 2014-10-30 |
| AU2013235344B2 (en) | 2017-03-16 |
| HK1208453A1 (en) | 2016-03-04 |
| EA031267B1 (ru) | 2018-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02082A (pl) | ||
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| MY178621A (en) | Deuterated cftr potentiators | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| IN2014KN02601A (pl) | ||
| MX2014002683A (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
| IN2015DN01156A (pl) | ||
| MX361815B (es) | Compuestos pirazolopirimidinicos como inhibidores de cinasas. | |
| MX2020004183A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
| WO2013134336A3 (en) | Inhibition of adaptor associated kinase 1 for the treatment of pain | |
| EA023222B8 (ru) | Пиразолилхиноксалиновые ингибиторы киназы | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| MX362550B (es) | Inhibidores ciclicos de glutaminasa. | |
| MX2013010016A (es) | Compuestos de quinazolina sustituidos con alquino y metodos uso. | |
| WO2014031438A3 (en) | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | |
| SG10201805392YA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| IN2014DN07224A (pl) | ||
| IN2015MN00002A (pl) | ||
| PH12016500735A1 (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| EA201590744A1 (ru) | Лечение рака tor киназными ингибиторами | |
| IN2014DN07220A (pl) | ||
| NZ707773A (en) | Methods of treating liver diseases | |
| WO2014160177A3 (en) | Quinazoline inhibitors of pi3k |